Drug Target Review – Issue #4 2016

Posted: 11 December 2016 | Drug Target Review | No comments yet

Included in this issue: Profiling proteins produced by cells to provide information about cell signalling pathways; HTS assays for the identification of small-molecule inhibitors of deubiquitinating enzymes; Preventing the spread of infectious diseases in transport hubs…

Drug Target Review - Issue 4 2016 - Front Cover

In Issue #4 2016 of Drug Target Review:

  • Foreword: The changing face of drug discovery
    Neil Weir, Chair, ABPI Innovation Board and Senior Vice President of Drug Discovery, UCB
  • Clinical optimism for antagonists targeting P2X3, P2X4 and P2X7 ion channels
    Anindya Bhattacharya, PhD, Janssen Research & Development, LLC
  • Screening: Diverse HTS assays for the identification of small-molecule inhibitors of deubiquitinating enzymes
    Kamyar Hadian, HelmholtzZentrum, München GmbH
  • Screening: Interview with Dr Lee E. Babiss, X-Rx Discovery
  • Translational proteomics: From the bench to the bedside
    Paula Díez and Manuel Fuentes, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL)
  • Versatile application of next-generation sequencing in pharmaceutics
    Pushpanathan Muthuirulan, PhD, National Institutes of Health
  • Valid biomarker signatures from liquid biopsies – how to standardise NGS
    Dominik Buschmann and Benedikt Kirchner, TUM School of Life Sciences and Ludwig-Maximilians-University Munich and Michael W. Pfaffl, TUM School of Life Sciences
  • Infectious Diseases: Tackling the spread of pathogens in transport hubs
    Ilpo Kulmala,VTT Ltd
  • Personalised Medicines: Interview with Dr Adrian Harel, CEO, Medicortex Finland Oy Pharma City
  • Personalised Medicines: Exploring the need for mutation-specific treatments in cystic fibrosis
    Caroline Richards, Editor, Drug Target Review

Issue #4 2016 is restricted - login or subscribe free to access

Screening the future innovations in drug discoveryThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • quarterly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here